Sanofi plans up to USD 1.6 billion investment in Germany: Handelsblatt
Advertisement
Frankfurt: French pharmaceutical company, Sanofi, is close to deciding on an investment ranging between 1.3 billion euros and 1.5 billion euros ($1.4-$1.6 billion) for its primary production facility in Frankfurt, Germany. This site manufactures the insulin brand Lantus, newspaper Handelsblatt reported on Monday.
Sanofi did not immediately respond to a request for comment, as per Reuters.
Among recent wins by Germany's ruling coalition to attract healthcare investments, Daiichi Sankyo said in February it would spend about 1 billion euros to boost its work on precision cancer drugs near Munich.
U.S. drugmaker Eli Lilly in November last year pledged to invest 2.3 billion euros to make obesity and diabetes drugs in Germany
Read also: Sanofi names Audrey Duval Derveloy as Executive Vice President, Global Head of Corporate Affairs
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.